Page 149 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY

PREDICTORS OF FREQUENT EXACERBATIONS IN (EX)SMOKING AND NEVER SMOKING ADULTS WITH SEVERE ASTHMA
Table 1. Comparison of (ex)smokers vs never smokers. (Ex)smokers (n=83)
Never smokers (n=70)
(13)
(13) (2-15) (5.4)
(500-1000)
(0.9) (1.1)
(20) (14) (20) (16) (5.6)
(13-46) (3.4-5.9) (0.1-0.34) (30-232) (38-84.4) (0.2-20.8)
p-value 0.133 0.026 0.195 0.531 0.793 0.052 NA NA 0.610 0.906 0.070 0.174 0.912 0.807 0.484
0.529 0.090 0.321 0.553 0.291
0.595 0.959 0.926 0.792 0.322 0.962
Age, years 53 Sex, % female 60 Age of asthma onset 43 Asthma duration, years 5 BMI, kg/m2 29.0 Positive family history of asthma, % 49 Current smoker, % 11 Pack years 9.00 ICS dose * 750 Chronic OCS use, % 28 Atopy, % 30 Chronic rhinosinusitis, % 21 GERD, % 37 ACQ-6 score 2.0 AQLQ 4.9
(10)
(14)
(1-14) 6 (5.2) 28.8
32 NA (5-20) NA (500-1000) 1000 29 44 31 38 (0.9) 1.9 (1.1) 4.8
Pb FEV1, % predicted
Pb FEV1/FVC, % predicted RV/TLC ratio, % predicted TLCOc/VA, % predicted PC20 (methacholine) mg/ml
FeNO, ppb
Blood neutrophils, 109 cells/L Blood eosinophils, 109 cells/L Total IgE, kU/L
Sputum neutrophil % Sputum eosinophil %
87 (20) 87 (14) 99 (20)
89 91 95
101 (16) 100 3.4 (4.6) 4.7
22 (13-42) 24 4.3 (3.5-5.5) 4.3 0.19 (0.1-0.395) 0.20 97 (24-247) 64 59.4 (39.3-72.6) 66.5 2.2 (0.2-25.6) 2.2
50 77 40
Data presented as percentage, mean (SD) or median (interquartile range). * ICS dose in fluticasone equivalent. Pb: postbronchodilator. ppb: parts per billion.
1
147